Poseida Therapeutics to Present Trial in Progress Poster for Phase 1 P-MUC1C-ALLO1 Study at the Society for Immunotherapy of Cancer Annual Meeting

(marketscreener.com) SAN DIEGO, Oct. 5, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. , a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it will present a Trial in Progress poster at the upcoming Society for Immunotherapy...https://www.marketscreener.com/quote/stock/POSEIDA-THERAPEUTICS-INC-109519711/news/Poseida-Therapeutics-to-Present-Trial-in-Progress-Poster-for-Phase-1-P-MUC1C-ALLO1-Study-at-the-Soci-41933074/?utm_medium=RSS&utm_content=20221005